Latest Headlines

Latest Headlines

Sanofi cozies up to top-tier labs with new R&D partnering effort

Sanofi has widened its R&D net, recruiting 7 of the U.S.'s most-respected research institutions in hopes of ferreting out some new ideas in early-stage drug development.

NBA, GE partner in multiyear deal to advance orthopedics and sports medicine

The National Basketball Association and GE Healthcare have signed a multiyear deal to work together to advance the prevention, diagnosis and treatment of musculoskeletal conditions among NBA players.

Soon-Shiong spawns yet another spinout in a tangled web of cancer R&D

Billionaire entrepreneur Patrick Soon-Shiong further complicated his sprawling biotech empire with another joint venture, teaming up with frequent collaborator Sorrento Therapeutics to launch a new company focused on oncology.

Recipharm takes a 25% stake in its drug-developing partner

Swedish contractor Recipharm has deepened its ties with partner Pharmanest, taking up a 25% stake in the biotech as the two collaborate on a pain drug.

Sanofi advances a one-shot malaria program as drug resistance spreads

Sanofi has re-upped with its partners at Medicines for Malaria Venture in hopes of developing a single-dose treatment for the infectious disease, advancing a pair of candidates through mid-stage development.

Theranos signs its first health insurer in a deal with Capital BlueCross

Long-stealthy inexpensive diagnostics provider Theranos has announced its first deal to become a diagnostics provider for a major health insurer: Capital BlueCross of Pennsylvania, which has about 1 million members. Last week, the company divulged that the FDA had cleared one of its tests for the first time.

U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine

On Tuesday, the U.S. government placed a large new order for Bavarian Nordic's smallpox vaccine while the company continues work to improve its formulation to offer more stockpiling flexibility.

Watch out AbbVie, Samsung Bioepis does fine with Humira biosimilar in PhIII

South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.

Israel's Oramed says $50M oral insulin deal with Sinopharm Capital-Hefei, not Guangxi Wuzhou

Israel's Oramed announced final-stage talks of a $50 million deal to sell China rights for its clinical-stage oral insulin candidate to a consortium of investors. The group consists of Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development.

Epic Sciences and LabCorp expand global reach with Asia clinical trials deal

Last year, San Diego's Epic Sciences said it would team up with diagnostics luminary LabCorp to make its tests available for European clinical trials. Now the companies are expanding their global footprint, extending their collaboration to provide Epic's tools for cancer clinical trials in Asia.